Spyre Therapeutics, Inc. (SYRE) Free cash flow 2016–2024
Spyre Therapeutics, Inc. (SYRE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$157.4MFY2024 · since FY2016: -$19.1M → -$157.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$157.4M | -57.6% |
| FY2023 | -$99.9M | -24.6% |
| FY2022 | -$80.2M | -47.7% |
| FY2021 | -$54.3M | +32.2% |
| FY2020 | -$80.1M | -19.2% |
| FY2019 | -$67.2M | -106.0% |
| FY2018 | -$32.6M | -29.3% |
| FY2017 | -$25.2M | -32.4% |
| FY2016 | -$19.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice